Sun's offer for rest of Taro faces Grand Slam wall
This article was originally published in Scrip
Executive Summary
Grand Slam Asset Management's opposition to Sun Pharma's offer to purchase the rest of Israel's Taro Pharmaceutical Industries may be justified but the former's higher asking price may also not be entirely reasonable, according to some analysts.